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There is much to celebrate at the end of the 
first decade of South Africa’s public sector 
antiretroviral therapy (ART) programme. An 
estimated 2 million South Africans had started 
ART by 2012, making ours the largest ART 
programme globally. ART coverage in adults, according to current 
guidelines, was estimated at 81% in 2012.[1] The prevalence of HIV 
is increasing, because people receiving ART are living longer.[2] In 
rural KwaZulu-Natal, adult life expectancy increased from 49.2 
years in 2003, just before the beginning of the ART programme, 
to 60.5 years in 2011.[3] Tremendous strides have been made in 
the prevention of mother-to-child transmission (PMTCT) of 
the virus. Almost 90% of pregnant, HIV-infected women access 
antiretrovirals (ARVs) either for their own health or for PMTCT, 
resulting in a 67% decline in new infections in children from 2009 
to 2012.[4] Further declines in new infections in children should be 
seen with the new PMTCT guidelines, which include prolonged 
ARVs for infants during breastfeeding, and combination ART for 
all mothers irrespective of CD4+ counts. ART access in eligible 
children has increased from 17% in 2009 to 67% in 2012.[4] We 
have even started a third-line ART programme.
The birth of our ART programme was difficult, to say the least. 
We should never forget the tragic loss of hundreds of thousands 
of South African lives as a result of delays in starting our ART 
programme. The AIDS-denialist views of former President 
Mbeki, including the absurd notion that ARVs, not HIV, were the 
cause of mortality, and the ill-informed promotion of nutrition 
as treatment for HIV by then health minister, Manto Tshabalala-
Msimang, were bitter pills to swallow for people living with 
HIV, grieving relatives, and healthcare workers. Civil society, 
notably the Treatment Action Campaign (TAC) and the AIDS 
Law Project, played a major role in forcing the government to 
implement ARVs for PMTCT, and later an ART programme. 
However, once the green light was reluctantly given to scale-up 
ART, the public sector responded well. 
Donors contributed significantly to the setting up and 
running of our ART programme, but unlike other African 
countries (except for Botswana), our ART programme is 
largely funded out of the national budget. The US President’s 
Emergency Plan for AIDS Relief and the Global Fund to 
Fight AIDS, Tuberculosis and Malaria have played key roles 
in funding our ART programme and providing technical 
assistance. Less well acknowledged is the critical role that 
donor-funded pilot ART projects have played in establishing 
the feasibility of public health ART programmes. Particularly 
noteworthy was the Khayelitsha project, which was jointly 
funded by Médecins Sans Frontières and the Western Cape 
government. Three ART clinics were opened in 2000 despite 
opposition from national government. Generic ARVs were 
imported from Brazil in 2001, provoking a statement from 
President Mbeki’s spokesman, Smuts Ngonyama, that this was 
tantamount to biological warfare. The high rates of virological 
suppression and retention in care of the first two years of the 
Khayelitsha ART project[5] were influential in the initial scale-
up of ART nationally and internationally.
A reduction in ARV costs has been one of the biggest achieve-
ments of the last decade. South Africa is a major global market 
player given the size of its national ART programme, and 
the Department of Health has been able to negotiate lower 
drug prices, to the benefit of other low- and middle-income 
countries. In 2000, ART cost around US$10 000 per year, while 
the currently used fixed-dose combination single tablet for 
first-line ART costs only US$129 per year. 
South Africa has the world’s highest number of people living 
with HIV, estimated to be 6.1 million in 2012,[1] nearly all of 
whom will require ART in the next decade. The estimated 
number of new HIV infections in South Africa decreased from 
640 000 in 2001 to 370 000 in 2012, which is gratifying, but 
most people infected in the next decade will also need ART. 
Major challenges lie ahead to achieve the expansion of the ART 
programme, particularly if South Africa adopts the new World 
Health Organization (WHO) ART initiation criterion of a 
CD4+ count <500 cells/µl. Task-shifting, such as nurse-initiated 
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but there is a need to train more nurses. Innovative models of patient 
care, such as adherence clubs,[6] should be developed, adapted to local 
contexts, and rolled out.
The biggest challenge for scaling up ART for the next decade will be 
retention in care. We know that over 2 million South Africans have 
started ART, but how many are still in care? Loss to follow-up increased 
with time and increasing clinic population size in a large South African 
ART programme,[7] suggesting that the massive ART programme 
expansion needed in the next decade will be accompanied by high 
attrition rates. Measures of retention in care at the facility level need to 
be collected routinely. Electronic pharmacy refills are increasingly being 
used and could easily identify people who are defaulting. Retention in 
care and rates of virological suppression according to years receiving 
ART should be used to identify poorly functioning clinics and regions.
The initial role for patient activist groups such as the TAC was crucial, 
given the state opposition to rational treatment for people living with 
HIV. Some might have thought that the job of activists was done once 
the national ART programme was launched and the current progressive 
Minister of Health was appointed. Unfortunately, the general lack of 
accountability in the public health services, as demonstrated by ongoing 
drug stock-outs, demonstrates the need for independent civil society 
groups to monitor service delivery, and where necessary, exert pressure 
on the health services to deliver their mandate.   
Finally, more resources need to be made available for operational 
research to support the ART programme. South African HIV researchers 
have been very productive, but almost all of their major achievements 
have been completed using resources from international grant agencies. 
Budgets were made available for research to support the national HIV 
programmes in the mid-2000s, but this was not sustained. The Medical 
Research Council has made good progress in leveraging extra funding 
for clinical research, indicating that political will exists to support more 
resources for research. 
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‘We know that over 2 million South 
Africans have started ART, but 
how many are still in care? ... the 
massive ART programme expansion 
needed in the next decade will be 
accompanied by high attrition rates.’
